Abstract
This book is an attempt to bring together in one volume existing information on the use of drugs to treat or prevent bone loss in children. Unless a child suffers from a genetic condition in which bone loss is flagrant the process of bone loss is often asymptomatic and if it occurs consequent to an underlying condition it does not attract medical attention. Therefore, this book undertakes to call to the reader’s attention the drugs available to prevent or treat pediatric bone loss. Even though no drugs have current approval for this purpose from the United States Food and Drug Administration (FDA), these chapters contain evidence of both safety and efficacy of antiresorptive and anabolic medications that have been used off-label in a variety of pediatric conditions.
Keywords
- Bone Loss
- Osteogenesis Imperfecta
- Prevent Bone Loss
- Recombinant Human Growth Hormone
- Pediatric Condition
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReference
Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Klein, G.L. (2014). Introduction. In: Klein, G. (eds) Bone Drugs in Pediatrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7436-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7436-5_1
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7435-8
Online ISBN: 978-1-4899-7436-5
eBook Packages: MedicineMedicine (R0)